• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Health’s ClearUP Named Best Sinus Pain Relief Solution of 2021 by Global Health & Pharma Magazine

Feb 7, 2022 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc., (Nasdaq: TIVC), a commercial-phase healthtech company focused on bioelectronic medicine, today announced that ClearUP® Sinus Pain Relief was named Best Sinus Pain Relief Solution of 2021 by Global Health...

Tivic Featured in ABC News Report: “New Bioelectronic Technologies Could Signal the Future of Medicine”

Jan 31, 2022 | Press Releases

Growing recognition of Bioelectronic Medicine as an important new therapeutic category SAN FRANCISCO – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase healthtech company focused on bioelectronic medicine, was one of two companies featured in...

Tivic Featured in ABC News Report: “New Bioelectronic Technologies Could Signal the Future of Medicine”

Jan 31, 2022 | Press Releases

Growing recognition of Bioelectronic Medicine as an important new therapeutic category SAN FRANCISCO – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase healthtech company focused on bioelectronic medicine, was one of two companies featured in...

Tivic Health Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform

Jan 19, 2022 | Press Releases

60-person clinical trial to investigate therapeutic device as an alternative to opioids following sinus surgeries SAN FRANCISCO – Tivic Health® Systems, Inc., (Nasdaq: TIVC), a commercial-phase healthtech company focused on bioelectronic medicine, today...

Tivic Health Systems, Inc. Announces Closing of Initial Public Offering

Nov 15, 2021 | Press Releases

MENLO PARK, Calif., Nov. 15, 2021 — Tivic Health Systems, Inc. (Nasdaq: TIVC) (“Tivic” or the “Company”), a commercial-phase bioelectronic medicine company, today announced the closing of its initial public offering of 3,000,000 shares of...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.